CONCORD, Calif.--(BUSINESS WIRE)--Dec. 30, 2005--Cerus Corporation (NASDAQ: CERS) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 safety trial for CRS-100, a Listeria-based immunotherapeutic designed to treat patients with cancer that has metastasized to the liver. Preclinical studies demonstrate the potential of Cerus’ proprietary Listeria strain (CRS-100) to stimulate a potent immune response against certain cancers in the liver. Data from some of these studies have been published in peer-reviewed journals, including a paper in the September 21, 2004, issue of the Proceedings of the National Academy of Sciences. Subject to FDA concurrence, Cerus intends to initiate a Phase I clinical trial in collaboration with investigators at leading cancer centers in the United States during the first half of 2006.
